[go: up one dir, main page]

EA201170595A1 - ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА - Google Patents

ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

Info

Publication number
EA201170595A1
EA201170595A1 EA201170595A EA201170595A EA201170595A1 EA 201170595 A1 EA201170595 A1 EA 201170595A1 EA 201170595 A EA201170595 A EA 201170595A EA 201170595 A EA201170595 A EA 201170595A EA 201170595 A1 EA201170595 A1 EA 201170595A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
hydrogen atom
formed together
lower alkyl
phenantroindolizidine
Prior art date
Application number
EA201170595A
Other languages
English (en)
Other versions
EA023622B1 (ru
Inventor
Такаси Икеда
Сейго Савада
Такаси Яегаси
Такеси Мацузаки
Сусуке Хасимото
Риута Ямазаки
Original Assignee
Кабусики Кайся Якулт Хонса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кабусики Кайся Якулт Хонса filed Critical Кабусики Кайся Якулт Хонса
Publication of EA201170595A1 publication Critical patent/EA201170595A1/ru
Publication of EA023622B1 publication Critical patent/EA023622B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Обеспечивают новое соединение, обладающее превосходным NFkB ингибирующим эффектом. В частности, раскрытое представляет собой соединение, представленное следующей формулой (1), или его соль, в которой Rпредставляет собой атом водорода, низшую алкильную группу или подобное; Rпредставляет собой атом водорода, низшую алкильную группу, атом галогена или подобное; Rпредставляет собой атом водорода, низшую алкильную группу, гидроксильную группу или атом галогена; Rпредставляет собой атом водорода или низшую алкилоксигруппу; Rпредставляет собой атом водорода, низшую алкилоксигруппу, атом галогена, гидроксильную группу, или метилендиоксигруппу, образованную вместе с R, или изопропилидендиоксигруппу, образованную вместе с R; Rпредставляет собой атом водорода, низшую алкилоксигруппу, или метилендиоксигруппу, образованную вместе с R, или изопропилидендиоксигруппу, образованную вместе с R; Rпредставляет собой атом водорода или низшую алкильную группу и Rпредставляет собой атом водорода, гидроксильную группу, аминогруппу, низшую алкилкарбонилоксигруппу или атом галогена.
EA201170595A 2008-10-23 2009-10-23 ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFκB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА EA023622B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008273556 2008-10-23
PCT/JP2009/005593 WO2010047126A1 (ja) 2008-10-23 2009-10-23 フェナンスロインドリジジン誘導体及びこれを有効成分とするＮＦκＢ阻害剤

Publications (2)

Publication Number Publication Date
EA201170595A1 true EA201170595A1 (ru) 2011-12-30
EA023622B1 EA023622B1 (ru) 2016-06-30

Family

ID=42119178

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170595A EA023622B1 (ru) 2008-10-23 2009-10-23 ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFκB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

Country Status (10)

Country Link
US (1) US8569327B2 (ru)
EP (1) EP2351753B1 (ru)
JP (1) JP5583589B2 (ru)
KR (1) KR101708512B1 (ru)
CN (1) CN102186850B (ru)
AU (1) AU2009307580B2 (ru)
CA (1) CA2740807C (ru)
EA (1) EA023622B1 (ru)
NZ (1) NZ592429A (ru)
WO (1) WO2010047126A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103446211B (zh) * 2013-09-24 2016-02-10 兰州理工大学 一种牛心朴子总生物碱及其制备方法和应用
CN104557909B (zh) * 2013-10-09 2019-01-01 中国医学科学院药物研究所 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途
KR101693035B1 (ko) 2015-01-14 2017-01-06 충북대학교 산학협력단 １,２,３,４-테트라하이드로퀴놀린-２-카르복실산 ｎ-(치환)페닐아미드 유도체 및 이의 용도
CN105924380B (zh) * 2015-02-27 2019-03-05 顺天乡大学校产学协力团 菲类化合物或其衍生物、以及含有该菲类化合物或其衍生物的治疗结核病用药物组合物
WO2016161538A1 (zh) * 2015-04-09 2016-10-13 中国医学科学院药物研究所 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途
JP6363765B1 (ja) * 2017-05-02 2018-07-25 スンチョンヒャン ユニバーシティ インダストリー アカデミー コーポレーション ファウンデーション 新規な化合物及びそれを含む結核の治療用薬学組成物
CN110294752B (zh) * 2018-03-21 2022-01-11 中国医学科学院药物研究所 光学纯(s)-3-新戊酰氧基-6,7-二甲氧基菲并吲哚里西啶的制备
CN110283170B (zh) * 2019-07-17 2020-11-06 清华大学 一种化合物制备及其在抑制多种肿瘤细胞生长中的应用
TWI811724B (zh) 2020-07-08 2023-08-11 財團法人國家衛生研究院 正股核糖核酸病毒之抑制劑
KR102249543B1 (ko) 2020-08-26 2021-05-11 한국화학연구원 페난트로인돌리지딘 및 페난트로퀴놀리지딘 알칼로이드 유도체, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 코로나바이러스감염증-19 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08319238A (ja) * 1995-05-24 1996-12-03 Asahi Chem Ind Co Ltd リン酸化酵素阻害剤
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子ＮＦκＢ活性化阻害剤
AU7446000A (en) 1999-09-27 2001-04-30 Japan As Represented By Director General Of Agency Of National Cancer Center Antitumor agents
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CA2474848A1 (en) 2002-02-15 2003-08-28 Yale University Novel tyloindicines and related processes, pharmaceutical compositions and methods
EP1604990A1 (en) * 2004-06-11 2005-12-14 National Health Research Institutes Phenanthroindolizidine alkaloids
CN101189968B (zh) * 2006-11-23 2011-06-01 南开大学 菲并吲哚里西啶和菲并喹喏里西啶衍生物及其盐在农药上的应用

Also Published As

Publication number Publication date
AU2009307580B2 (en) 2015-04-23
JPWO2010047126A1 (ja) 2012-03-22
WO2010047126A1 (ja) 2010-04-29
CN102186850B (zh) 2014-10-29
CN102186850A (zh) 2011-09-14
US20110201637A1 (en) 2011-08-18
EP2351753A4 (en) 2012-05-30
NZ592429A (en) 2012-10-26
US8569327B2 (en) 2013-10-29
CA2740807A1 (en) 2010-04-29
EP2351753B1 (en) 2015-02-11
KR20110079661A (ko) 2011-07-07
EA023622B1 (ru) 2016-06-30
CA2740807C (en) 2016-12-20
EP2351753A1 (en) 2011-08-03
KR101708512B1 (ko) 2017-02-20
AU2009307580A1 (en) 2010-04-29
JP5583589B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
EA201170596A1 (ru) ФЕНАНТРОИНДОЛИЗИДИНОВОЕ СОЕДИНЕНИЕ И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ ДЕЙСТВУЮЩЕГО ИНГРЕДИЕНТА
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
TN2012000237A1 (en) An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
DE602008000754D1 (de) Tropanverbindungen
ECSP099091A (es) Profarmaco de compuesto de cinamida
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
RS53679B1 (en) FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
WO2009028387A1 (ja) プロテアーゼ阻害剤耐性を有する癌の治療薬

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM